Alpha Lipoic Acid Plus Omega-3 Fatty Acids for Vestibulodynia Associated With Painful Bladder Syndrome
| Autor: | Dania Gambini, Raffaele Felice, Filippo Murina, Alessandra Graziottin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Docosahexaenoic Acids medicine.drug_class Visual analogue scale Vulvodynia Amitriptyline Cystitis Interstitial Tricyclic antidepressant Gastroenterology Antioxidants 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Surveys and Questionnaires medicine Humans chemistry.chemical_classification 030219 obstetrics & reproductive medicine Thioctic Acid business.industry Obstetrics and Gynecology Interstitial cystitis Analgesics Non-Narcotic Middle Aged medicine.disease Eicosapentaenoic acid Surgery Treatment Outcome chemistry Eicosapentaenoic Acid McGill Pain Questionnaire Docosahexaenoic acid Drug Therapy Combination Female business 030217 neurology & neurosurgery Polyunsaturated fatty acid medicine.drug |
| Zdroj: | Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 39(3) |
| ISSN: | 1701-2163 |
| Popis: | Objective This study assessed the effectiveness of alpha lipoic acid (ALA) plus omega-3 polyunsaturated fatty acids (n-3 PUFAs) in combination with amitriptyline therapy in patients with vestibulodynia/painful bladder syndrome (VBD/PBS). Methods Women with VBD/PBS were randomly assigned to receive amitriptyline or amitriptyline plus a commercially available preparation (ALAnerv Age; Alfa Wassermann, Bologna, Italy) containing, in 2 capsules, ALA 600 mg plus docosahexaenoic acid 250 mg and eicosapentaenoic acid 16.67 mg. Symptoms of burning and pain were assessed using a 10-cm visual analog scale and the short form of the McGill-Melzack Pain Questionnaire. Results Among 84 women who were randomized, the mean ± standard deviation dose of amitriptyline was 21.7 ± 6.6 mg/day, without statistical difference between the two groups. Pain, as assessed using both the pain rating index of the visual analog scale and the short-form McGill Pain Questionnaire, decreased significantly in both trial groups, with a greater effect seen with the addition of ALA and n-3 PUFAs. The addition of ALA/n-3 PUFAs to amitriptyline treatment was also associated with improvements in dyspareunia and pelvic floor muscle tone. The overall incidence of adverse events was low, and none led to treatment discontinuation. Conclusions The addition of ALA/n-3 PUFAs to amitriptyline treatment in patients with VBD/PBS appears to improve outcomes and may allow for a lower dosage of amitriptyline, which may lead to fewer adverse effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|